CASE 16

**Patient:** A 14 year old boy from Petchaburee

**Chief Complaint:** multiple ulcerations on trunk

**Present Illness:** He presented with non-painful ulcerations on lower neck and right upper trunk for 4 month duration. The lesion was first described as tiny red bumps which were asymptomatic. It initially started on the right shoulder. Later on, the lesion increased in numbers, and began to rupture and evolved into several small ulcers which were enlarging. A month after the eruption, he received local traditional herbal treatment without any improvement. Instead, the lesions worsened and became foul-smelling so he decided to come to our hospital.

**Review of Systems:** weight loss of 3 kg in 4 months

**Past History:** unremarkable

**Family History:** non contributory

**Dermatological Examination** (Figure 16.1-2): Right neck, chest and trunk: multiple discrete well defined deep ulcers with thick necrotic debris in variable size from 5-12 cm

![Figure 16.1](image1.png)  ![Figure 16.2](image2.png)
**Physical Examination:** Left anterior cervical 1.5 cm and Left submandibular 2 cm, firm to hard consistency, not tender, no hepatospleenomegaly

**Investigations:** normal CBC, LFT, CXR, chest and abdominal CT scan, negative bone marrow and lumbar puncture study.

**Histopathology (S10-7479) (Figure 16.3-4):**
- Dense diffuse mixed cell infiltrate of predominantly neutrophilic, extravasated erythrocytes and numerous large atypical cells in dermis and subcutaneous tissue
- Atypical cells showing large rounded vesicular nuclei, with prominent nucleoli and pale abundant eosinophilic cytoplasm

![Figure 16.3, H&E 40x](image1)
![Figure 16.4, H&E 400x](image2)
![Figure 16.5, CD3 100x](image3)
![Figure 16.6, CD30, 200x](image4)
![Figure 16.7, EMA 200x](image5)
**Immunohistochemistry** (Figure 16.5-7):
- Inflammatory-cells positive: both CD3 and CD20
- Atypical cells positive: CD30 and EMA

**Diagnosis:** Primary cutaneous anaplastic large cell lymphoma (C-ALCL) with secondary regional lymphadenopathy

**Presenter:** Marinya Pongpudpunth

**Consultant:** Penpun Wattanakrai

**Discussion:**

Primary cutaneous CD30 lymphoproliferative disorders (LPDs) are the second most common group of CTCLs, accounting for approximately 30% of CTCLs. This group includes primary cutaneous anaplastic large cell lymphoma (C-ALCL), lymphomatoid papulosis (LyP), and borderline cases. It is now generally accepted that C-ALCL and LyP form a spectrum of disease, and that histologic criteria alone are often insufficient to differentiate between these 2 ends of this spectrum. Thus, the clinical course is needed to articulate in the process of diagnosis.\(^1\)

According to WHO-EORTC classification for cutaneous lymphomas 2005, primary cutaneous anaplastic large cell lymphoma (CALCL) is defined phenotypically by CD30 expression of at least 75% of the large lymphoid cells with an anaplastic, pleomorphic, or immunoblastic cytomorphology.\(^1,2\) The clinical evidence or history of LyP, MF, or another type of CTCL must be excluded.

C-ALCL affects mainly adults with a male to female ratio of 2-3:1. It is uncommon in children and adolescents under 20 years of age.\(^3,5\) Most patients present with a solitary firm, large and often ulcerated nodule which is usually asymptomatic. The head and extremities are the site of
Multifocal lesions are seen in about 20% of the patients. Without therapy, spontaneous regression occurs in 10-42% of tumors, as seen in LyP. These lymphomas frequently relapse in the skin. Extracutaneous dissemination occurs in approximately 10% of the patients, mainly involving the regional lymph nodes.

Histologically, there is a diffuse, nonepidermotropic infiltrate with cohesive sheets of large CD30+ tumor cells. In most cases the tumor cells have the characteristic morphology of anaplastic cells, showing round, oval, or irregularly shaped nuclei, prominent eosinophilic nucleoli, and abundant pale cytoplasm. Less commonly (20%-25%), they have a nonanaplastic (pleomorphic or immunoblastic) appearance. Clusters of small reactive lymphocytes are often found within and around the tumor. Ulcerating lesions may show a LyP-like histology with an abundant inflammatory infiltrate of reactive T cells, histiocytes, eosinophils and/or neutrophils, and relatively few CD30 cells. In such cases epidermal hyperplasia may be prominent.

Immunophenotypically, the neoplastic cells generally show an activated CD4+T-cell phenotype with variable loss of CD2, CD5, and/or CD3, and frequent expression of at least one cytotoxic proteins (granzyme B, TIA-1, perforin). Some cases (less than 5%) have a CD8+ T-cell phenotype. CD30 must be expressed by the majority (more than 75%) of the neoplastic T cells. Unlike systemic CD30+ lymphomas, most C-ALCLs express the cutaneous lymphocyte antigen (CLA), but do not express epithelial membrane antigen (EMA) and anaplastic lymphoma kinase (ALK), indicative of the 2:5 chromosomal translocation or its variants. Unlike Hodgkin and Reed-Sternberg cells in Hodgkin disease, staining for CD15 is generally negative. Coexpression of CD56 is
observed in rare cases, but does not appear to be associated
with an unfavorable prognosis.\textsuperscript{13}

Genetically, clonal rearrangement of TCR genes
can be found in 90\% of the cases.\textsuperscript{14} The (2;5)(p23;q35)
translocation is rarely found in C-ALCL which is a characteristic
feature of systemic ALCL.\textsuperscript{12}

The prognosis is usually favorable with a 10-year
disease-related survival exceeding 90\%.\textsuperscript{3,6} Patients presenting
with multifocal skin lesions and patients with involvement of
only regional lymph nodes have a similar prognosis to patients
with only skin lesions.\textsuperscript{3} No difference in clinical presentation,
clinical behavior, or prognosis is found between cases with an
anaplastic morphology and cases with a nonanaplastic
(pleomorphic or immunoblastic) morphology.\textsuperscript{3,7}

In regard to prognosis and treatment, it is crucial
to differentiate primary and secondary cutaneous ALCL in order
to avoid aggressive over or under treatment in both groups. In
patients presenting with a solitary or few localized nodules or
tumors, the first choice of treatment is radiotherapy or surgical
excision. Patients presenting with multifocal but only a few
lesions, can best be treated with radiotherapy or with low-dose
methotrexate, as in LyP.\textsuperscript{3,15} Patients developing extracutaneous
disease or in rare instance with rapidly progressive skin disease
should be treated with doxorubicin based multiagent
chemotherapy.

In this case, after the negative extensive work
up on systemic involvement, due to the presence of multifocal
ulcerations with possibly secondary regional lymphadenopathy,
he was diagnosed as stage III disease (over two single
cutaneous tumors and extranodal with two or more nodal areas
on both sides of the diaphragm). Thus, the systemic
chemotherapy was chosen. Before the session began, due to
low grade fever and lymphocytosis, the superimposed infection of the ulcerations was suspected and subsequently treated with systemic antibiotic and local wound care until becoming clear. To date, the patient received four courses of chemotherapy in which he tolerated well. There is a dramatic improvement of the skin lesions that are healing nicely. The remaining superficial erosions are still seen but no new lesions observed. The cervical lymphadenopathy was disappeared after the first session of chemotherapy. He is still undergoing the rest of the treatment process.

References


